Apobiologix Launches Pegfilgrastim Autoinjector In Canada

The First Biosimilar Version Of Amgen’s Original Neulasta Autoinjector

 
• By Rosalind Rei

Apobiologix’s new Lapelga autoinjector that the firm has just introduced in Canada is only the second on-body pegfilgrastim device to launch after Amgen’s Neulasta original.

Neutrophil, a white blood cell, 3D illustration
Pegfilgrastim treats neutropenia, characterised by low counts of a white blood cell known as neutrophils • Source: Shutterstock

More from Products

More from Generics Bulletin